$GWAV

Greenwave Technology Solutions, Inc. (GWAV): Unregistered Sales of Equity Securities

Greenwave Technology Solutions, Inc. (GWAV) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02. Unregistered Sales of Equity Securities To the extent required by Item 3.02, the information contained in Items 5.03 and 8.01 is incorporated herein by reference. The Private Placement (as defined below) with the Investors (as defined below) was exempt from registratio

Original reporting
Published Sep 11, 2026, 9:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 9:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$GWAV
Neutral
medium confidence
Mentioned
$GWAV
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$GWAVNeutralLow
01

Why it matters

The $3.75 M raise provides modest liquidity but introduces preferred shareholders with conversion rights and veto powers over certain corporate actions.

02

Market read

Primary disclosure of a small private placement; limited immediate market impact for GWAV.

03

What to watch

The preferred terms grant holders veto rights over key corporate actions, which could affect future strategic moves.

Relevance 5/10Novelty 6/10Timing: filing Sep 11 2026 (same‑day disclosure)

Background

Greenwave Technology Solutions filed an 8‑K reporting a private placement of Series B convertible preferred stock.

Company-level read

Ticker impact

$GWAVNeutralMedium confidence
Context

Closed a private placement of 3,750 Series B convertible preferred shares for $3.75 million on Sep 9 2026.

Expected impact

Limited upside; price may inch higher on the news but no major move expected.

Evidence & confidence

Small raise ($3.75 M) for a micro‑cap; conversion price $5.24 limits immediate dilution, so market reaction is likely muted.

Market effects

Minimal; adds a small amount of capital to the niche tech‑services sector.

None; company is US‑based with no broader regional effect.

Insignificant; micro‑cap filing does not influence global markets.

Counterpoint

If conversion triggers >4.99% ownership limit, holders may block future equity actions, potentially pressuring the stock.

Key entities

  • Greenwave Technology Solutions, Inc.

    Issuer of the Series B convertible preferred stock.

  • Series B Preferred Stock Holders

    Five institutional investors receiving the preferred shares.

Related articles

$GWAVHighAI 9/10

Greenwave Announces Receipt of Additional Delinquency Notice from Nasdaq

Greenwave Technology Solutions said Nasdaq issued an additional delinquency notice on May 21, 2026 for its delayed Q1 2026 Form 10-Q filing, citing noncompliance with Nasdaq Listing Rule 5250(c)(1). The company previously received a delinquency notice for its late 2025 Form 10-K. Nasdaq gives until June 22, 2026 to submit a compliance plan; trading remains on Nasdaq under “GWAV.”

$CRWVHighAI 8/10

Why CoreWeave Is Tumbling Hard While the Market Is Soaring

CoreWeave (CRWV) shares fell 3.5% midday, underperforming the S&P 500's 0.9% rise, amid a $3.5B convertible note offering and 35M share ATM program, raising dilution concerns. The company has $72B in liabilities and a $626M Q2 net loss, despite strong demand and revenue growth. Analysts maintain an average $144 price target.

$QBTSHigh

QBTS Stock Rallies As U.S. Backs Quantum Expansion

D-Wave Quantum Inc. (QBTS) stock rose 7.87% on U.S. government backing and positive analyst coverage. The company secured up to $100M in CHIPS Act funding, and BMO Capital initiated coverage with a $35 price target. QBTS reported $24.6M annual revenue, negative margins, and $296.6M in cash. NTT DOCOMO's use of its quantum tech also drove interest.

$SNYLowAI 8/10

Sanofi announces new $925 million flu vaccine facility in Toronto

Sanofi announced a $925 million flu vaccine facility in Toronto, with partial funding from the federal government ($55 million) and the City of Toronto. The project is expected to create 300 jobs and enhance local vaccine supply. Premier Doug Ford emphasized Ontario's investment philosophy and the importance of domestic vaccine production.